title: Epirubicin as part of a multi-agent chemotherapy protocol for canine lymphoma.
abstract: The aim of the study was to report the outcome of treatment of 97 dogs with lymphoma that received a multi-agent chemotherapy protocol containing epirubicin as the primary anthracycline. Seventy-five dogs received a 25-week protocol with no maintenance phase whilst 22 dogs received a maintenance phase. Complete response rate was 96% and time to first relapse (TTR) and overall survival (OS) time for all dogs were 216 and 342 days, respectively. Dogs with T-cell lymphoma and those classified as WHO substage b had significantly poorer OS times and TTR. The protocol was well tolerated with toxicity similar to doxorubicin-containing protocols. Epirubicin as part of a multi-agent protocol is safe and effective in the treatment of canine multicentric lymphoma. There is a high initial response rate and an overall median survival time that is similar to other published doxorubicin-containing protocols.
authors.affiliation: Small Animal Teaching Hospital, University of Liverpool, Wirral, UK. jelliott@liverpool.ac.uk
authors.forename: J W
authors.initials: JW
authors.lastname: Elliott
authors.forename: P
authors.initials: P
authors.lastname: Cripps
authors.forename: A M
authors.initials: AM
authors.lastname: Marrington
authors.forename: I A
authors.initials: IA
authors.lastname: Grant
authors.forename: L
authors.initials: L
authors.lastname: Blackwood
mesh_terms: D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D004283:Dog Diseases / Q000188:drug therapy*; D004285:Dogs; D015251:Epirubicin / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D008223:Lymphoma / Q000188:drug therapy / Q000662:veterinary*; D008297:Male; D012189:Retrospective Studies
chemical_list: D000903:Antibiotics, Antineoplastic; D015251:Epirubicin